vs
BIOCRYST PHARMACEUTICALS INC（BCRX）与Mativ Holdings, Inc.（MATV）财务数据对比。点击上方公司名可切换其他公司
Mativ Holdings, Inc.的季度营收约是BIOCRYST PHARMACEUTICALS INC的3.0倍（$463.1M vs $156.4M），BIOCRYST PHARMACEUTICALS INC同比增速更快（7.5% vs 1.0%），过去两年BIOCRYST PHARMACEUTICALS INC的营收复合增速更高（19.6% vs -3.8%）
BioCryst Pharmaceuticals是一家总部位于美国北卡罗来纳州达勒姆的制药企业，属于后期发展阶段的生物科技公司，聚焦于治疗罕见重症的口服药物研发。其研发的抗病毒药物帕拉米韦（商品名Rapivab）于2014年12月获得美国FDA批准，此后也陆续在日本、韩国与中国获批上市。
Mativ Holdings是一家全球特种材料制造商，主要生产高性能先进聚合物、无纺布、过滤解决方案及功能性涂层材料，服务医疗、工业、消费品、航空航天、能源等领域，业务遍及北美、欧洲及亚太地区。
BCRX vs MATV — 直观对比
营收规模更大
MATV
是对方的3.0倍
$156.4M
营收增速更快
BCRX
高出6.5%
1.0%
两年增速更快
BCRX
近两年复合增速
-3.8%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $156.4M | $463.1M |
| 净利润 | — | $100.8M |
| 毛利率 | — | 18.8% |
| 营业利润率 | 13.6% | 2.2% |
| 净利率 | — | 21.8% |
| 营收同比 | 7.5% | 1.0% |
| 净利润同比 | — | 6620.0% |
| 每股收益（稀释后） | $0.00 | $1.87 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BCRXMATV
| Q1 26 | $156.4M | — | ||
| Q4 25 | $406.6M | $463.1M | ||
| Q3 25 | $159.4M | $513.7M | ||
| Q2 25 | $163.4M | $525.4M | ||
| Q1 25 | $145.5M | $484.8M | ||
| Q4 24 | $131.5M | $458.6M | ||
| Q3 24 | $117.1M | $498.5M | ||
| Q2 24 | $109.3M | $523.8M |
净利润BCRXMATV
| Q1 26 | — | — | ||
| Q4 25 | $245.8M | $100.8M | ||
| Q3 25 | $12.9M | $-3.2M | ||
| Q2 25 | $5.1M | $-9.5M | ||
| Q1 25 | $32.0K | $-425.5M | ||
| Q4 24 | $-26.8M | $1.5M | ||
| Q3 24 | $-14.0M | $-20.8M | ||
| Q2 24 | $-12.7M | $-1.4M |
毛利率BCRXMATV
| Q1 26 | — | — | ||
| Q4 25 | 97.7% | 18.8% | ||
| Q3 25 | 98.6% | 19.3% | ||
| Q2 25 | 98.3% | 19.7% | ||
| Q1 25 | 96.9% | 15.0% | ||
| Q4 24 | 95.4% | 16.9% | ||
| Q3 24 | 97.3% | 18.8% | ||
| Q2 24 | 98.4% | 20.8% |
营业利润率BCRXMATV
| Q1 26 | 13.6% | — | ||
| Q4 25 | 64.0% | 2.2% | ||
| Q3 25 | 18.6% | 3.1% | ||
| Q2 25 | 18.2% | 3.8% | ||
| Q1 25 | 14.6% | -88.8% | ||
| Q4 24 | -3.4% | 0.6% | ||
| Q3 24 | 6.6% | 1.4% | ||
| Q2 24 | 8.0% | 2.0% |
净利率BCRXMATV
| Q1 26 | — | — | ||
| Q4 25 | 60.5% | 21.8% | ||
| Q3 25 | 8.1% | -0.6% | ||
| Q2 25 | 3.1% | -1.8% | ||
| Q1 25 | 0.0% | -87.8% | ||
| Q4 24 | -20.4% | 0.3% | ||
| Q3 24 | -12.0% | -4.2% | ||
| Q2 24 | -11.6% | -0.3% |
每股收益（稀释后）BCRXMATV
| Q1 26 | $0.00 | — | ||
| Q4 25 | $1.13 | $1.87 | ||
| Q3 25 | $0.06 | $-0.06 | ||
| Q2 25 | $0.02 | $-0.18 | ||
| Q1 25 | $0.00 | $-7.82 | ||
| Q4 24 | $-0.13 | $0.03 | ||
| Q3 24 | $-0.07 | $-0.38 | ||
| Q2 24 | $-0.06 | $-0.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $259.0M | $84.2M |
| 总债务越低越好 | — | $1.0B |
| 股东权益账面价值 | — | $498.7M |
| 总资产 | $465.1M | $2.1B |
| 负债/权益比越低杠杆越低 | — | 2.07× |
8季度趋势，按日历期对齐
现金及短期投资BCRXMATV
| Q1 26 | $259.0M | — | ||
| Q4 25 | $274.7M | $84.2M | ||
| Q3 25 | $212.9M | $97.1M | ||
| Q2 25 | $260.0M | $95.6M | ||
| Q1 25 | $295.1M | $84.0M | ||
| Q4 24 | $320.9M | $94.3M | ||
| Q3 24 | $96.8M | $162.2M | ||
| Q2 24 | $78.4M | $133.4M |
总债务BCRXMATV
| Q1 26 | — | — | ||
| Q4 25 | — | $1.0B | ||
| Q3 25 | — | $1.0B | ||
| Q2 25 | — | $1.1B | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $1.2B |
股东权益BCRXMATV
| Q1 26 | — | — | ||
| Q4 25 | $-119.2M | $498.7M | ||
| Q3 25 | $-387.9M | $397.4M | ||
| Q2 25 | $-421.6M | $416.6M | ||
| Q1 25 | $-451.9M | $428.2M | ||
| Q4 24 | $-475.9M | $858.5M | ||
| Q3 24 | $-468.6M | $882.3M | ||
| Q2 24 | $-475.6M | $898.0M |
总资产BCRXMATV
| Q1 26 | $465.1M | — | ||
| Q4 25 | $514.2M | $2.1B | ||
| Q3 25 | $446.4M | $2.0B | ||
| Q2 25 | $457.2M | $2.1B | ||
| Q1 25 | $480.0M | $2.1B | ||
| Q4 24 | $490.4M | $2.4B | ||
| Q3 24 | $491.3M | $2.6B | ||
| Q2 24 | $472.4M | $2.6B |
负债/权益比BCRXMATV
| Q1 26 | — | — | ||
| Q4 25 | — | 2.07× | ||
| Q3 25 | — | 2.63× | ||
| Q2 25 | — | 2.66× | ||
| Q1 25 | — | 2.67× | ||
| Q4 24 | — | 1.30× | ||
| Q3 24 | — | 1.32× | ||
| Q2 24 | — | 1.29× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $19.3M |
| 自由现金流经营现金流 - 资本支出 | — | $8.0M |
| 自由现金流率自由现金流/营收 | — | 1.7% |
| 资本支出强度资本支出/营收 | — | 2.4% |
| 现金转化率经营现金流/净利润 | — | 0.19× |
| 过去12个月自由现金流最近4个季度 | — | $93.8M |
8季度趋势，按日历期对齐
经营现金流BCRXMATV
| Q1 26 | — | — | ||
| Q4 25 | $292.0M | $19.3M | ||
| Q3 25 | $41.6M | $72.8M | ||
| Q2 25 | $41.3M | $57.6M | ||
| Q1 25 | $-27.5M | $-15.9M | ||
| Q4 24 | $-5.2M | $24.1M | ||
| Q3 24 | $8.2M | $37.6M | ||
| Q2 24 | $-1.4M | $46.1M |
自由现金流BCRXMATV
| Q1 26 | — | — | ||
| Q4 25 | $291.2M | $8.0M | ||
| Q3 25 | $40.3M | $66.7M | ||
| Q2 25 | $41.1M | $48.9M | ||
| Q1 25 | $-27.7M | $-29.8M | ||
| Q4 24 | $-5.9M | $2.0M | ||
| Q3 24 | $8.2M | $25.5M | ||
| Q2 24 | $-1.5M | $37.4M |
自由现金流率BCRXMATV
| Q1 26 | — | — | ||
| Q4 25 | 71.6% | 1.7% | ||
| Q3 25 | 25.3% | 13.0% | ||
| Q2 25 | 25.2% | 9.3% | ||
| Q1 25 | -19.0% | -6.1% | ||
| Q4 24 | -4.5% | 0.4% | ||
| Q3 24 | 7.0% | 5.1% | ||
| Q2 24 | -1.4% | 7.1% |
资本支出强度BCRXMATV
| Q1 26 | — | — | ||
| Q4 25 | 0.2% | 2.4% | ||
| Q3 25 | 0.8% | 1.2% | ||
| Q2 25 | 0.1% | 1.7% | ||
| Q1 25 | 0.1% | 2.9% | ||
| Q4 24 | 0.5% | 4.8% | ||
| Q3 24 | 0.1% | 2.4% | ||
| Q2 24 | 0.1% | 1.7% |
现金转化率BCRXMATV
| Q1 26 | — | — | ||
| Q4 25 | 1.19× | 0.19× | ||
| Q3 25 | 3.23× | — | ||
| Q2 25 | 8.12× | — | ||
| Q1 25 | -859.91× | — | ||
| Q4 24 | — | 16.07× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BCRX
| ORLADEYO | $148.3M | 95% |
| Other revenues | $5.0M | 3% |
| License revenue | $3.0M | 2% |
MATV
| Other | $208.7M | 45% |
| SAS Segment | $157.4M | 34% |
| FAM Segment | $97.0M | 21% |
